Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.79 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | FABP3 | P05413 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | PTAFR | P25105 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037179 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL15709161 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL416515 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL234634 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL25354838 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL23188433 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL235532 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL45162 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL22492184 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL178155 | 0.95 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729052-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND TETRAHYDROCANNABINOL AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729049-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND AXITINIB AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250281596-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. | 2025-09-11 | — | — | US | disclosed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | disclosed |
| EP-4445898-A1 | SUSTAINED RELEASE DOSAGE FORMS COMPRISING COMPLEXES OF LOW SOLUTIBILITY COMPOUNDS, AND METHODS FOR THEIR PREPARATION | Emoviar PharmaCon GmbH (DE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4445899-A1 | SUSTAINED RELEASE DOSAGE FORMS COMPRISING COMPLEXES OF LOW SOLUTIBILITY COMPOUNDS, AND METHODS FOR THEIR PREPARATION | Emoviar PharmaCon GmbH (DE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240261223-A1 | MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS | SUNVAX MRNA THERAPEUTICS (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4351618-A2 | TREM-2/DAP-12 INHIBITORS FOR TREATING LUNG DISEASE AND INJURY AND COMBINATIONS THEREOF | Signablk, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022245553-A2 | TREM-2/DAP-12 INHIBITORS FOR TREATING LUNG DISEASE AND INJURY AND COMBINATIONS THEREOF | SIGNABLK, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20210214401-A1 | MANUFACTURING METHOD OF NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN AND NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN MANUFACTURED BY THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-07-15 | — | — | US | disclosed |
| US-20040213833-A1 | certain MMP inhibitory peptides improve the targeting of liposomes to cancer cells and enhance the uptake thereof by such cells | CTT CANCER TARGETING TECHNOLOGIES OY (FI) | 2004-10-28 | — | — | US | disclosed |
| EP-1469830-A2 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS USING PRESSURE NOZZLES | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1438021-A2 | METHODS AND APPARATUS FOR EXTRUSION OF VESICLES AT HIGH PRESSURE | Esperion Therapeutics Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003063821-A2 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS USING PRESSURE NOZZLES | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003026588-A2 | METHODS AND APPARATUS FOR EXTRUSION OF VESICLES AT HIGH PRESSURE | ESPERION THERAPEUTICS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030017520-A1 | High-efficiency assay for protein mannosyl transferases | PHARMACIA & UPJOHN COMPANY | 2003-01-23 | — | — | US | disclosed |
| EP-1260591-A1 | High-efficiency assay for protein mannosyl transferases | Pharmacia & Upjohn Company (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6099857-A | LIPID, VESICLE KIT; DRUG DELIVERY | WASHINGTON UNIVERSITY (US) | 2000-08-08 | — | — | US | disclosed |
| WO-1997021729-A9 | METHODS AND COMPOSITIONS FOR MODULATING VESICLE RELEASE | — | 1997-11-06 | — | — | WO | disclosed |
| WO-1995031183-A1 | CELL MEMBRANE FUSION COMPOSITION AND METHOD | WASHINGTON UNIVERSITY (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281596-A1 | IONIZABLE CATIONIC COMPOUND | SLC11A2, ABCB4, ARG2 | SMN1; SMN2 1684/4885NR5A2 2715/4885NR5A1 3268/4885 |
| US-20240261223-A1 | MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS | PLIN3, PHOSPHO1, SGMS2 | SMN1; SMN2 3060/4885NR5A2 4080/4885NR5A1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.